MRI-based model to predict chemotherapy benefit for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial uses a special MRI-based computer model to predict how well chemotherapy will work before surgery for triple-negative breast cancer. It aims to help doctors tailor treatment to each patient's likely response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 or older.
- Confirmed triple-negative breast cancer (or a similar type like ER/PR 1-10% positive).
- Tumor size/stage that may benefit from chemotherapy before surgery.
- Must have had a breast MRI and a biopsy sample taken before starting chemotherapy.
- Plans to receive standard chemotherapy then surgery, or already on this path.
- Able to undergo chemotherapy and surgery, with good overall health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special imaging before and after treatment to see if it can predict how well triple-negative breast cancer responds to chemotherapy plus immunotherapy given before surgery. Participation could help doctors tailor future treatments.
This study tests an artificial intelligence (AI) tool that helps doctors choose the best chemotherapy plan for people with triple-negative breast cancer before surgery. By analyzing your tumor tissue, the AI aims to guide treatment to improve outcomes.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
Hear when a new Breast Neoplasm Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.